drugset
drugset / Trial / NCT03942211

A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag

NCT03942211 ↗

Phase 2 Terminated 10 enrolled Actelion
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Oral selexipag is commercially available in several countries for the treatment of a particular group of pulmonary hypertension (PH) called pulmonary arterial hypertension (PAH). The aim of the present study is to investigate whether selexipag could be helpful to treat patients with another form of PH called sarcoidosis-associated pulmonary hypertension (SAPH).

Timeline

Start
2021-02-26
Primary completion
2023-04-19
Completion
2023-04-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Selexipag Small molecule 200 ug Oral
Subject Selexipag Small molecule 400 ug Oral
Subject Selexipag Small molecule 600 ug Oral
Subject Selexipag Small molecule 800 ug Oral
Subject Selexipag Small molecule 1000 ug Oral
Subject Selexipag Small molecule 1200 ug Oral
Subject Selexipag Small molecule 1400 ug Oral
Subject Selexipag Small molecule 1600 ug Oral

Indications

pulmonary hypertension